Product Wiki · Recalls · UK OPSS (Office for Product Safety and Standards)

Exclusive, Active Intense, Unify & Illuminate, Tone Boosting Gel — product safety report 2411-0078

UK OPSS (Office for Product Safety and Standards) · GB · 2024-11-14 · Product Safety Report

Compiled from an official source — the facts on this page are reproduced from the issuing authority’s own published notice, which is linked on this page. No AI-generated text appears on this page. How we use AI →
Agency
UK OPSS (Office for Product Safety and Standards)
Recall identifier
product-safety-report-makari-de-suisse-active-intense-tone-boosting-gel-2411-0078
Date of alert
2024-11-14
Country / jurisdiction
GB
Authority classification
Product Safety Report
Risk type
product-safety-report
Brand
Makari De Suisse
Product category
cosmetics
Barcode (EAN/GTIN)
098864008461
Reported risk: The product presents a serious chemical risk as following analysis the cream was found to contain 300mg/kg clobetasol propionate. Clobetasol propionate is prohibited in cosmetic products as exposure to it could cause skin irritation and may damage the endocrine system. The product does not meet the requirements of Regulation (EC) 1223/2009 or the Cosmetic Products Enforcement Regulations 2013.
What to do

Check whether your product matches this notice (name, batch, dates). If it does, stop using it and follow the instructions in the official notice — refund, return, repair or disposal are set by the issuing authority and the business, and they differ per recall. Official notice from UK OPSS (Office for Product Safety and Standards) →

Primary source: https://www.gov.uk/product-safety-alerts-reports-recalls/product-safety-report-m

Verify each fact at the issuing agency before acting. Recall scope, affected lots, and remediation instructions may be updated by the agency after our last sync.

Related

ProductGuru indexes recall and safety-alert records from ~30 public agency registries. We are not lawyers, regulators or product-safety consultants. This page restates what the named agency published; consult the primary source above (or qualified counsel in your jurisdiction) before any commercial, medical or safety decision.